Royal Bank Of Canada Coherus Bio Sciences, Inc. Transaction History
Royal Bank Of Canada
- $479 Billion
- Q4 2024
A detailed history of Royal Bank Of Canada transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 11,069 shares of CHRS stock, worth $13,061. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,069
Previous 13,415
17.49%
Holding current value
$13,061
Previous $13,000
15.38%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding CHRS
# of Institutions
133Shares Held
70MCall Options Held
1.16MPut Options Held
39.5K-
Black Rock Inc. New York, NY11.8MShares$13.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$13.2 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.28MShares$6.23 Million0.02% of portfolio
-
Rubric Capital Management LP New York, NY5.26MShares$6.21 Million0.12% of portfolio
-
Tang Capital Management LLC San Diego, CA3.65MShares$4.31 Million0.38% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $91.7M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...